Study of CT1190B CAR-T Cell Therapy for Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Evaluating Safety, Effectiveness, and Cell Behavior in Phase 1 Trial

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and cellular metabolism of CT1190B CAR-T cell therapy in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma B-NHL. This Phase 1, open-label study aims to understand how CT1190B cells behave in the body and impact the disease. The trial plans to enroll between 6 and 24 participants who have previously undergone treatment for B-NHL but need further therapy due to disease progression or intolerance to prior treatments. Participants will receive an infusion of CT1190B CAR-T cells designed to target their cancer. This single-arm study involves one treatment group receiving this experimental therapy. The study includes close monitoring for adverse events and determination of the maximum tolerated dose within 28 days after infusion. Follow-up evaluations will continue for up to 12 months to assess response rates, remission duration, survival outcomes, and other key measures. During the trial, participants will undergo regular assessments including physical exams, laboratory tests, and imaging to measure tumor response and monitor safety. Researchers will track overall response rate, complete remission rate, progression-free survival, and overall survival at various intervals up to one year. Participants are required to agree to long-term follow-up for up to 15 years to monitor ongoing effects. Total involvement includes the treatment period plus extended safety and outcome monitoring.

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma